<DOC>
	<DOC>NCT02953704</DOC>
	<brief_summary>The purpose of this prospective, longitudinal, noninterventional study is to describe clinical characteristics, evolution of disease burden, and treatment patterns in patients with select subcategories of essential thrombocythemia (ET) or myelofibrosis (MF).</brief_summary>
	<brief_title>Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia, Essential</mesh_term>
	<criteria>MF cohort: Diagnosis of MF and lowrisk using DIPSS risk categorization OR intermediate1 risk by DIPSS by reason of age alone. ET cohort: Diagnosis of ET and age ≥ 60 years OR history of thromboembolic events OR currently receiving ETdirected therapy (eg, hydroxyurea, anagrelide, interferon, busulfan, ruxolitinib, etc). Willing and able to provide written informed consent. Willing and able to complete patient assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel. Under the supervision of a physician for the current care of MF or ET. Individuals who are participating in blinded investigational drug studies. Individuals who are participating in Incyte investigational/interventional drug trials (company or investigatorsponsored studies) until they have completed the 30day end of study visit. Life expectancy ≤ 6 months. Diagnosis of secondary acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, or secondary thrombocytosis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Myelofibrosis</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>clinical characteristics</keyword>
	<keyword>disease burden</keyword>
	<keyword>patient-reported outcomes</keyword>
</DOC>